Related by context. All words. (Click for frequent words.) 77 deCODE BreastCancer 67 ductal breast cancer 66 Menopausal hormone therapy 66 deCODE ProstateCancer TM 65 Homocysteine levels 65 OnDose TM 65 ovarian endometrial 65 lobular breast cancer 65 deCODE AF TM 64 epithelial ovarian cancer 64 methylation markers 64 histologic subtype 64 Rectal cancer 64 atypical hyperplasia 64 Radical prostatectomy 64 Uterine cancer 64 MammaPrint R 64 HER2 expression 63 Relapsing remitting MS 63 invasive lobular carcinoma 63 tumor histology 63 gynecologic malignancy 63 proton MR spectroscopy 63 mammographically 63 breast endometrial 63 leiomyomas 63 colorectal neoplasia 63 cytologic 63 serum biomarkers 63 LungAlert TM 62 colorectal adenoma 62 chlamydial infection 62 HER2 overexpression 62 genetic variants associated 62 endometrial cancers 62 advanced adenoma 62 Colon polyps 62 conditional logistic regression 62 multivariate logistic regression 62 CSF Tf 62 EUS FNA 62 PSA nadir 62 prognostic indicators 62 hormone receptor negative 62 skeletal metastases 62 Prostate specific antigen 62 serous ovarian cancer 62 atypical ductal hyperplasia 62 bronchopulmonary dysplasia BPD 62 hereditary breast cancer 62 K ras mutations 62 HNSCC 62 echocardiographic parameters 62 hormone receptor status 62 squamous cell lung cancer 62 Heavy menstrual bleeding 62 intracranial stenosis 62 CHD CVD 62 clinico pathological 62 Multiple logistic regression 61 Metastatic colorectal cancer 61 hematopoietic cancers 61 Framingham Risk Score 61 deCODE Glaucoma TM 61 sCJD 61 gestational diabetes mellitus GDM 61 ductal carcinomas 61 Vascular dementia 61 obstructive coronary artery 61 Corus CAD 61 BRCA1 mutation carriers 61 FDG PET scans 61 precursor lesions 61 APOE genotype 61 Adjuvant chemotherapy 61 advanced neoplasia 61 Elevated PSA 61 Sentinel node biopsy 61 antigen PSA 61 thyroid nodules 61 Venous thromboembolism 61 Cystatin C 61 colorectal cancer CRC 61 atypical lobular hyperplasia 61 CIN2 + 61 #.#ng/ml 61 PSADT 61 invasive ductal cancer 61 hydroxy vitamin D 61 node metastases 61 advanced adenomas 61 pancreatic adenocarcinoma 61 hormone therapy estrogen 61 HIV tropism 61 molecular abnormalities 61 low expressors 61 postoperative mortality 61 malignant polyps 61 SLNB 61 lobular cancer 61 TGFBR1 * 6A 61 lymph node biopsies 61 frequently benign tumor 61 subclinical atherosclerosis 61 PLX STROKE targeting 60 Endometrial cancer 60 BRCA gene mutation 60 postmenopausal hormone 60 stratifying patients 60 BRCA mutations 60 Renal Cell Carcinoma RCC 60 Genetic predisposition 60 nuchal translucency 60 carcinomatosis 60 ductal cancer 60 albumin excretion 60 Epigenomics proprietary 60 endometrial biopsy 60 tamoxifen Nolvadex ® 60 Reynolds Risk Score 60 Chronic lymphocytic leukemia CLL 60 molecular biomarker 60 proliferative retinopathy 60 generalized epilepsy 60 Folate deficiency 60 operable breast cancer 60 deCODE T2 TM 60 penetrance 60 prostate cancer CaP 60 ADPKD 60 Cardiorespiratory fitness 60 Ovary removal 60 ovarian malignancy 60 BRCA2 carriers 60 prognostic markers 60 cervical carcinoma 60 breast uterine 60 CYP#D# genotype 60 colorectal lung 60 relapsed MM 60 allogeneic HSCT 60 differentiated thyroid 60 invasive ductal breast cancer 60 clinically localized prostate 60 Epithelial ovarian cancer 60 atypia 60 Androgen deprivation therapy 60 Multivariate logistic regression 60 mammographic density 60 pelvic malignancies 60 extracolonic findings 60 urine albumin 60 carotid artery blockage 60 nonmelanoma skin cancers 60 PROLARIS 60 thromboembolic disease 60 invasive lobular 60 diagnostic biomarker 60 microalbumin 60 Prostate Specific Antigen PSA 60 endometrial carcinoma 60 Folic acid supplements 60 radiation chemoradiation 60 Chlamydia trachomatis infection 60 HER2 positive cancers 60 nonmelanoma 60 lobular carcinomas 60 colonoscopic 60 hamartomas 60 specific antigen PSA 60 spirometric 60 BEXXAR Therapeutic Regimen 60 nodal metastasis 60 kidney urologic 60 adrenocortical cancer 60 CIN3 60 HER2 amplified 60 Telomere length 60 unresectable tumors 60 DNA methylation markers 60 Basal cell 60 renal cell carcinomas 60 chromosomal aberrations 60 Chronic pancreatitis 60 Uncontrolled hypertension 60 familial clustering 60 retrospective cohort 60 SUVmax 60 carotid stenosis 59 System IPSS 59 abnormal cytology 59 malignant ovarian 59 prognostic variables 59 FDG PET imaging 59 diffuse gastric 59 Genetic variants 59 glycosylated hemoglobin HbA1c 59 underwent surgical resection 59 apolipoprotein E4 59 Medullary thyroid cancer 59 p# biomarker 59 percutaneous biopsy 59 pelvic ultrasound 59 atherogenic dyslipidemia 59 histological subtypes 59 multigene expression test 59 malignant neoplasm 59 endometriosis ovarian cysts 59 Shark cartilage 59 gastric cardia 59 intra arterial chemotherapy 59 premalignant lesion 59 bowel polyps 59 prostate pancreatic 59 gestational diabetes mellitus 59 Coronary artery bypass grafting 59 Computed Tomography CT scans 59 pancreatic lung 59 cervical cancer precursors 59 Sentinel Lymph Node Biopsy 59 invasive ductal 59 Logistic regression 59 Ectopic pregnancy 59 Squamous 59 multivariable Cox 59 Routine screening 59 CYT# potent vascular disrupting 59 DVT PE 59 abnormal glucose metabolism 59 Skin sterol 59 uterine ovarian 59 adenomatous polyps 59 endocrine therapies 59 urine dipstick 59 BRCA mutation carriers 59 NMIBC 59 bladder ovarian 59 radiochemotherapy 59 BRCA2 mutations 59 PLAC test 59 multimodality therapy 59 CTAP# Capsules 59 perioperative morbidity 59 BRCA2 mutation carriers 59 haematologic 59 multivariable analysis 59 breast carcinomas 59 preoperative staging 59 postmenopausal hormones 59 multivariable adjusted 59 adnexal masses 59 hormonally sensitive 59 Alzheimer disease vascular dementia 59 gene BRCA2 59 transvaginal sonography 59 ovulatory cycles 59 D dimer 59 ovarian breast 59 AAT deficiency 59 gastric carcinoma 59 postoperative chemotherapy 59 LRP5 59 chronic periodontitis 59 basal cell carcinoma squamous 59 lobular carcinoma 59 nonischemic 59 endometrial hyperplasia 59 Darapladib 59 breast cancer subtypes 59 clinicopathologic 59 breast carcinoma 59 thyrotropin levels 59 etiologic 59 Nonalcoholic fatty liver 59 hormonally responsive 59 testicular germ cell 59 catheter angiography 59 transfusion syndrome 59 nonmelanoma skin cancer 59 underwent coronary angiography 59 miRview ™ squamous 59 ovarian cervical 59 polyp recurrence 59 PITX2 59 urolithiasis 59 oncologic outcomes 59 precancerous tumors 59 chromosomal anomalies 59 ASCUS 59 cardiac channelopathies 59 Oncotype 59 HIV HCV coinfected 59 hepatocellular carcinoma liver 59 ovarian pancreatic 59 neurocognitive impairment 59 nonfasting triglyceride levels 58 multivariate Cox 58 serum PTH 58 Thyroid nodules 58 colonoscopy sigmoidoscopy 58 Flexi Scope 58 Glioblastoma multiforme GBM 58 phytoestrogen intake 58 tumor subtypes 58 immunochemical fecal occult 58 postoperative pulmonary 58 gestational hypertension 58 hematological disorders 58 peritoneal cancer 58 aerodigestive tract 58 poor metabolizers 58 papillary renal cell carcinoma 58 CT coronary angiography 58 atherothrombotic disease 58 malignant nodules 58 liver metastasis 58 Fetal Fibronectin Test 58 Ischemic strokes 58 prostate cancer PCa 58 perfusion MRI 58 mucinous 58 #q# deletion 58 electrophysiologic 58 APOE e4 58 white matter hyperintensities 58 GnRH agonists 58 narcolepsy cataplexy 58 Hurthle cell 58 Soy isoflavones 58 Recurrence Score 58 EGFR mutation status 58 KRAS status 58 pCR 58 adjuvant systemic 58 immunohistochemical staining 58 congenital toxoplasmosis 58 immunochemical 58 PCNSL 58 dyslipidaemia 58 lung pancreatic 58 elevated CRP 58 subclinical hyperthyroidism 58 malignant lesions 58 pathological hallmark 58 Platinol ® cisplatin 58 MCF7 58 Liver biopsy 58 pharmacogenetic tests 58 neurosensory 58 thyroid carcinoma 58 2D 4D ratio 58 grade cervical dysplasia 58 Colorectal cancer CRC 58 obstructive CAD 58 premenstrual syndrome PMS 58 #F FDG PET 58 nonalcoholic steatohepatitis NASH 58 antitumor effect 58 recurrent miscarriage 58 colorectal polyps 58 subclinical disease 58 DNA methylation patterns 58 undergo prostate biopsy 58 nonsmall cell lung cancer 58 coronary calcification 58 Combination antiretroviral therapy 58 BRCA2 gene mutation 58 bronchogenic carcinoma 58 thrombophilia 58 axillary dissection 58 adnexal mass 58 spiral computed tomography 58 Cholesterol lowering statins 58 antiplatelet therapies 58 OVA1 ® 58 severe hepatic dysfunction 58 sensitivity specificity 58 grade gliomas 58 Glioblastoma Multiforme GBM 58 chronic bilirubin encephalopathy 58 Coronary angiography 58 neurocognitive function 58 internalizing disorders 58 serum GGT 58 cervical intraepithelial neoplasia 58 multifactorial disease 58 glycated hemoglobin levels 58 dose ionizing radiation 58 obstructive coronary 58 BRCA1 mutations 58 Squamous cell 58 benign nodules 58 genetic aberrations 58 Subgroup analyzes 58 nondiabetic patients 58 multi infarct dementia 58 immunotherapeutic approaches 58 hypermethylated 58 undergone radical prostatectomy 58 diabetes mellitus DM 58 CT colonography CTC 58 elevated serum ALT 58 anti Mullerian hormone 58 hepatocellular carcinomas 58 lobular involution 58 KRAS oncogene 58 core needle biopsies 58 Adjuvant therapy 58 postoperative complication 58 hypervascular tumors 58 progesterone receptor PR 58 faulty BRCA genes 58 coronary revascularizations 58 eTag assays 58 elevated LDL cholesterol 58 metastatic lymph nodes 58 Von Willebrand disease 58 multivariate analyzes 58 TMPRSS2 ERG fusion 58 pulmonary dysfunction 58 thyroglobulin 58 peritoneal carcinomatosis 58 thiopurine 58 metastatic renal 58 glial tumors 58 nodal metastases 58 FullTerm 58 dose Iluvien 58 clinicopathological 58 psychiatric comorbidities 58 basal cell carcinoma BCC 58 Haptoglobin 58 PCA3 scores 58 colorectal cancer incidence 58 Polycystic ovary syndrome PCOS 58 Adenomas 58 TT genotype 58 multiple logistic regression 58 endometrial breast 58 biochemical relapse 58 precancerous cervical 57 microsatellite instability 57 abnormal Pap test 57 quantitative gene expression 57 abdominal computed tomography 57 Lymph node 57 sociodemographic characteristics 57 cystatin C 57 salpingo oophorectomy 57 pancreatic prostate 57 recurrent metastatic 57 intestinal biopsy 57 convergent validity 57 promoter hypermethylation 57 histological subtype 57 miRNA biomarkers 57 genomewide 57 Papillary 57 prognostic biomarkers 57 BSGI MBI 57 lung colorectal 57 troponin T 57 extracolonic 57 abnormal lipid 57 LV dysfunction 57 sentinel lymph node biopsy 57 hereditary predisposition 57 recurrent bladder 57 genetic polymorphisms 57 PCA3 gene 57 STRIDE PD 57 urine cytology 57 carotid plaques 57 chorioamnionitis 57 FDG-PET/CT 57 N telopeptide 57 renal carcinoma 57 LQTS 57 postoperative pathology 57 axillary lymph nodes 57 carotid artery narrowing 57 cardiac troponin T 57 nonvertebral fracture 57 molecular biomarkers 57 polycystic ovary syndrome PCOS 57 genetic biomarkers 57 R0 resection 57 abnormal mammogram 57 naturally occurring estrogen 57 distant metastasis 57 parous women 57 glioma rarer 57 fibroadenomas 57 neurologic complications 57 CINtec ® PLUS 57 immunohistochemical 57 adjuvant radiation 57 Estrogen receptor positive 57 Computed tomography 57 thoracoscopic lobectomy 57 curable cancers 57 fluorodeoxyglucose positron emission tomography 57 Gliomas 57 lung cancer NSCLC 57 Oncotype DX breast cancer 57 LHRH agonists 57 lymphoid tumors 57 NATRECOR ® 57 unmeasured confounding 57 genomewide association studies 57 serum thyroglobulin 57 BRACAnalysis ® 57 breast pancreatic 57 commercialize deforolimus 57 Human papillomavirus 57 gauge vitrectomy 57 SRBD 57 cardioembolic stroke 57 glycated hemoglobin HbA1c 57 gallstone disease 57 LHRH receptor positive 57 bladder tumors 57 multivariable logistic regression 57 male hormones androgens 57 Fasting glucose 57 colorectal bowel 57 Premenopausal 57 androgen excess 57 cytoreduction 57 Plaque psoriasis 57 putative biomarkers 57 Heavy snorers 57 lymph node enlargement 57 leiomyoma 57 invasive carcinomas 57 ependymomas 57 microRNA biomarkers 57 Multivariate analysis 57 transrectal ultrasound guided 57 PRESEPT study 57 estrogen progestin therapy 57 intima media thickness 57 grade cervical intraepithelial 57 postoperative AF 57 coronary computed tomography 57 androgen deprivation 57 inconclusive Pap 57 metastatic gastric 57 telomere lengths 57 Lung transplantation 57 transcranial Doppler 57 pre malignant lesions 57 fibrate drugs 57 validating biomarkers 57 arterial thickening 57 Logistic regression analysis 57 somatoform disorders 57 percutaneous cryoablation 57 prostate carcinoma 57 Allergic asthma 57 lymphomas leukemias 57 soluble CD# ligand 57 fundus photography 57 fusion enhancers 57 colon rectal 57 variant angina 57 Acute myeloid leukemia 57 antidiabetic medication 57 Genetic variations 57 pretest probability 57 chromosomal disorders 57 postoperative morbidity 57 left ventricular diastolic 57 MSMB 57 sarcosine 57 prostate specific 57 Aortic stenosis 57 CLIA certified laboratories 57 allele frequencies 57 alpha1 antitrypsin deficiency 57 prospective observational studies 57 F FDG PET 57 overt nephropathy 57 androgen deficiency 57 oesophageal adenocarcinoma 57 albumin excretion rate 57 Thyroid disorders 57 acute leukemias 57 metastatic liver 57 Acute lymphoblastic leukemia 57 seminoma 57 malignant pleural mesothelioma 57 APTIMA HPV 57 testicular tumors 57 artery embolization 57 Rev Dex 57 HGPIN 57 Calcium intake 57 BRAF gene mutations 57 allostatic load 57 oligodendrogliomas 57 BRCA1 BRCA2 57 Subgroup analysis 57 vaginal progesterone gel 57 serum PSA 57 include ColorectAlert TM 57 sonographic diagnosis 57 skin sterol 57 cause cardiac channelopathies 57 progesterone receptor negative 57 P2V TM 57 metastatic bladder 57 diagnostic modality 57 STK# gene 57 rosuvastatin #mg 57 smoldering myeloma 57 diagnose Alzheimer disease 57 neoadjuvant radiation 57 epithelial ovarian 57 intestinal polyps 57 metabolomic profiling 57 fetal chromosomal abnormalities 57 Cholangiocarcinoma 57 colonic polyps 57 test FOBT 57 APOE ε4 57 Circulating tumor cells 57 beta carotene supplementation 57 metabonomics 57 progestagen 57 medically inoperable 57 helical CT 57 Hyperlipidemia 57 HbA1C 57 plasma homocysteine levels 57 basal cell nevus syndrome 57 cisplatin resistant 57 Her2 positive 57 CVD mortality 57 Genetic profiling 57 antiplatelet medications 57 chronic thromboembolic pulmonary 57 androgen suppression therapy 57 BRCA2 mutation 57 tested eribulin 57 Positron emission tomography 57 aromatase inhibitors AIs 57 telogen effluvium 57 subclinical hypothyroidism 57 HER2 positivity 57 Pneumococcal vaccines 57 esophagogastric 57 immunosuppressive regimens 57 CMV infection 57 IgA deficiency 57 cTnT 57 qualitative serum 57 FGFR2 gene 57 myocardial viability 57 comorbid illnesses 56 endometrial kidney 56 coronary arteriography 56 FUS protein 56 carcinoid 56 sociodemographic factors 56 bacterial prostatitis 56 aneuploidy screening 56 inhaled bronchodilators 56 Sleep disturbances 56 aldosterone antagonist 56 Cotinine 56 USPSTF recommends 56 eosinophilic pneumonia 56 hydroxyvitamin D levels 56 pleural mesothelioma 56 Hip fracture 56 benign proliferative breast 56 Abbott Trilipix 56 SGPT 56 carotid atherosclerosis 56 Bone density 56 meta regression 56 metastatic neuroendocrine tumors 56 Hair follicle 56 BCR ABL mutations 56 postoperative atrial fibrillation 56 malignant brain 56 nonmetastatic 56 ano genital warts 56 B7 H3 56 Anal cancer 56 gastrointestinal GI cancers 56 NSCLC tumors 56 inherited mutations 56 familial aggregation 56 Glioblastoma multiforme 56 recurrent ovarian 56 metastatic lesions 56 polyp detection 56 RECAF TM 56 lumbar disk herniation 56 seminomas 56 chromosomal mutations 56 lymphocyte count 56 thermogram 56 gemcitabine Gemzar 56 breast cancer susceptibility genes 56 recurrent NSCLC 56 grade serous ovarian 56 BRAF inhibitors 56 HbF 56 prostate carcinogenesis 56 MTHFD1L gene 56 ferroportin levels 56 CYP#D# gene 56 semiquantitative 56 ABCB1 56 aneuploid cells 56 estrogen receptor negative 56 ε4 56 adenomatous 56 intraductal 56 Hormone pills 56 oophorectomy 56 DEXA scans 56 symptomatic VTE 56 chromosomal rearrangement 56 Oral contraceptive 56 bronchial hyperresponsiveness 56 polycystic ovarian syndrome PCOS 56 psoriatic arthritis PsA 56 Atopic dermatitis 56 colorectal polyp 56 mycosis fungoides 56 perinatal outcomes 56 BRCA mutation 56 preoperative chemotherapy 56 Waldenstrom macroglobulinemia 56 Abdominal ultrasound 56 MTWA testing 56 Malignant glioma 56 Screening mammography 56 FFR measurements 56 GABRA2 56 squamous intraepithelial lesions 56 biochemical recurrence 56 cervical prostate 56 monogenic 56 Zyclara Cream 56 epithelial tumors 56 methylation biomarkers 56 MAGE A3 ASCI 56 faulty BRCA2 gene 56 blood coagulation disorders 56 potentially cancerous polyps 56 hsCRP levels 56 underwent resection 56 Cervista HPV HR 56 differential gene expression 56 differentiate squamous 56 Hypertensive heart 56 Premenopausal women 56 empiric therapy 56 Surgical excision 56 Parkinsonian Syndromes 56 BioMAP ® Systems 56 Surgical resection 56 FDG uptake 56 cardio respiratory fitness 56 MDRD equation 56 Basal Cell 56 miRNA profiling 56 myelofibrosis polycythemia vera 56 cervix uteri 56 ALA PDT 56 Elastography 56 Thalomid ® 56 intravenous bisphosphonates 56 BRAF V# mutation 56 urine NGAL 56 Flexible sigmoidoscopy 56 cervical cytology 56 precancer 56 fetal aneuploidy 56 antiangiogenic agents 56 lymphatic cancers 56 hepatic lesions 56 breast cancer gene mutation 56 LHRH antagonists 56 relapsing remitting MS RRMS 56 secondary amenorrhea 56 chromosomal alterations 56 transabdominal 56 Testicular cancer 56 Angiograms carry slight 56 MiCK assay 56 Endothelial dysfunction 56 microalbumin test 56 endpoint assays 56 mutated K ras 56 lung esophageal 56 anovulatory infertility 56 Univariate 56 Premature menopause 56 endometrial ovarian 56 carbohydrate intolerance 56 miRview ™ mets 56 cervicitis 56 sputum cytology 56 Minimally invasive procedures 56 logistic regression analysis 56 miRview TM 56 PITX2 methylation 56 susceptibility loci 56 spontaneous regression 56 familial hypercholesterolemia 56 prostate abnormalities 56 Systemic lupus erythematosus SLE 56 contralateral breast cancer 56 Carcinoid tumors 56 Malignant mesothelioma 56 ADVEXIN therapy 56 somatic mutations 56 invasive prenatal 56 precancerous polyp 56 thyroid deficiency 56 CytoCore develops cost 56 Mitomycin C 56 Carotid artery stenting 56 gastric adenocarcinoma 56 neoplasias 56 confidence interval #.#-#.# 56 abnormal mammograms 56 histologies 56 Cojocaru correspondent 56 Prostate Specific Antigen 56 renal cortical 56 raloxifene Evista 56 Accelerated Partial Breast Irradiation 56 abnormal lipid levels 56 pathologic fractures 56 coronary revascularization 56 Socioeconomic status 56 Alessandro Riva 56 metabolomic profiles 56 visit www.rtanswers.org 56 glycosylated hemoglobin levels 56 recurrent myocardial infarction 56 testosterone supplementation 56 PCOD 56 Epidemiologic studies 56 Contraceptive pill 56 CAM2 Q family 56 esthesioneuroblastoma rare form 56 neovascular 56 Kaplan Meier curve 56 kidney allograft 56 debulking surgery 56 chemotherapy cisplatin 56 MYH9 gene 56 baseline LDH 56 intensive statin therapy 56 Malignant gliomas 56 KIF6 carriers 56 osteosarcomas 56 MRgFUS 56 cytoreductive surgery 56 diagnosing coronary artery 56 HCV antibody 56 neutrophil gelatinase associated lipocalin 56 colorectal prostate 56 nodal dissection 56 transcranial Doppler ultrasound 56 lymph node removal 56 ErbB2 positive 56 coronary CTA 56 unruptured aneurysm 56 GBA mutations 56 HNPCC 56 tau protein tangles 56 Multivariable logistic regression 56 SSc 56 noncancer 56 CPAP adherence 56 adenoma recurrence 56 ALT elevation 56 molar pregnancy 56 Colorectal cancer screening 56 thoracic aortic disease 56 Anthracycline 56 diabetic kidney 56 prognostic indicator 56 breast lesions 56 SELDI TOF MS 56 Hepatocellular carcinoma 56 transferrin saturation 56 exhaled nitric oxide 56 HER2 gene 56 lactate dehydrogenase LDH 56 angiographically 56 hepatorenal syndrome 56 recurrent VTE 56 noninvasive outpatient 56 chemosensitivity 56 precancerous cervical lesions 56 familial pancreatic cancer 56 NNRTI resistance 56 HER2 positive breast 56 histopathologic findings 56 Descriptive statistics 56 PSMA ADC 56 CSF biomarkers 56 Lewy bodies DLB 56 definite stent thrombosis 56 serum estradiol 56 Provectus Pharmaceuticals specializes 56 Oncotype DX colon cancer 56 embryonal rhabdomyosarcoma 56 ovarian lung 56 Fasting blood glucose 56 detecting colorectal cancer 56 amniotic fluid leakage 56 thalidomide Thalomid 56 localized prostate 56 Lowering cholesterol 56 guaiac 56 nondemented 56 severe periodontitis 56 Sezary syndrome 56 elevated fasting glucose 56 serum selenium 56 ependymoma 56 serum biomarker 56 lung ovary 56 BRCA gene mutations 56 TRAIL R1 56 locoregional recurrence 56 dysplastic lesions caused 56 cTnT levels 55 asymptomatic carotid stenosis 55 scintigraphic 55 multidetector row 55 cervical lesions 55 Radiofrequency ablation 55 thetreatment 55 KRAS mutation 55 logistic regression analyzes 55 Breslow thickness 55 Li Fraumeni 55 Glioblastomas 55 Male infertility 55 genomic biomarker 55 chest radiographs 55 preintervention 55 visit www.genenews.com 55 immunosuppressive medications 55 CYP#C# [001] 55 Cardiotoxicity 55 familial predisposition 55 euthymic patients 55 Non Melanoma Skin 55 ChromoCure develops 55 spinal metastases 55 PreDx DRS 55 colorectal neoplasms 55 electron beam computed tomography 55 lethal arrhythmias 55 pelvic lymphadenectomy 55 inherited retinal degeneration 55 hip BMD 55 Pre implantation genetic 55 glomerular filtration 55 stage IIIA 55 neurodevelopmental impairment 55 renal biopsy 55 selenium intake 55 Coronary artery calcium 55 NPM1 mutation 55 antiproliferative effects 55 recurrent venous thromboembolism 55 intraobserver 55 deCODE MI TM 55 localized renal 55 hypercoagulable 55 hemoglobin A1c HbA1c 55 pretreatment serum 55 neoadjuvant therapy 55 systemic amyloidosis 55 cancerous polyps 55 clinically detectable 55 undergo mastectomy 55 taxane therapy 55 coronary blockages 55 KRAS mutations 55 gonococcal infection 55 Stage IIB 55 triple quadrupole mass spectrometers 55 myelogenous leukemia 55 chest radiography